Bristol-Myers Squibb vs Dell: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Dell was founded in 1984 by Michael S. Dell and is led by Michael S. Dell.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Dell
- Founded
- 1984
- Headquarters
- Round Rock, Texas
- Current CEO
- Michael S. Dell
- Employees
- 97,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Dell
Michael S. Dell
Dell Technologies possesses one of the most famous, foundational founding stories in the history of the personal computer revolution, rooted in an aggressive, direct-to-consumer arbitrage strategy executed entirely from a college dorm room.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Dell
- Michael S. Dell1984–present
Founder, Chairman, and Chief Executive Officer
Michael Dell's bold, aggressive strategic maneuvers transformed the company from a successful consumer PC manufacturer into a global leader in complex enterprise data center infrastructure and advanced cloud computing.
Source - Kevin Rollins2004–2007
President and Chief Executive Officer
As CEO from 2004 to 2007, he oversaw a period of severe stagnation, losing the company's #1 PC market share position to HP, forcing Michael Dell to return and retake control.
Source - Jeff Clarke2017–present
Vice Chairman and Chief Operating Officer
As Vice Chairman and Co-COO, he is the primary operational architect of Dell's Infrastructure Solutions Group, transforming the company from a PC maker into a massive enterprise IT vendor.
Source - David Kennedy2025–present
Chief Financial Officer
As Chief Legal Officer, he navigated the highly contentious 2013 leveraged buyout that took the company private, and the equally complex 2018 transaction that returned it to the public markets.
Source
Timeline: Bristol-Myers Squibb and Dell side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1984Dell
PC's Limited Founded
Michael Dell starts PC's Limited from his University of Texas dorm room using a direct-sales PC model.
1988Dell
Dell Goes Public
Dell Computer Corporation completes its initial public offering and scales internationally.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2001Dell
Dell Becomes Largest PC Maker
Dell becomes the world's largest PC maker by market share, validating the direct model at global scale.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2007Dell
Michael Dell Returns as CEO
Michael Dell returned as chief executive in January 2007, replacing Kevin Rollins.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2013Dell
Dell Goes Private
Michael Dell and Silver Lake take Dell private in a leveraged buyout to reposition the company away from public-market pressure.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2016Dell
EMC Acquired
Dell completes the EMC acquisition, creating Dell Technologies and expanding into enterprise storage, infrastructure, and VMware-linked assets.
2018Dell
Dell Returns to Public Markets
Dell Technologies returns to public-market trading through a complex transaction involving its VMware tracking stock.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2021Dell
VMware Spin-Off
Dell completes the VMware spin-off, simplifying the corporate structure and reducing debt.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Dell
PC Brands Simplified
Dell introduces simplified Dell, Dell Pro and Dell Pro Max PC brand tiers at CES 2025.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Dell
Record $113.5B Fiscal Year
Dell reports record fiscal 2026 revenue of $113.5B, $64.1B of AI server orders and a $43B AI backlog.
2026Dell
$95B AI Server Backlog
Q2 fiscal 2027 revenue rises 58% to $47.0B; AI orders hit $60.9B and backlog reaches $95B; full-year guidance raised to about $192B.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Dell
- EMC Corporation2016$67B
- Quest Software2012$2.4B
- Perot Systems2009$3.9B
- Alienware2006Undisclosed
Questions about Bristol-Myers Squibb vs Dell
Who is the CEO of Bristol-Myers Squibb Company and Dell Technologies Inc.?
Bristol-Myers Squibb Company is led by Christopher Boerner and Dell Technologies Inc. is led by Michael S. Dell. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Dell Technologies Inc.?
Bristol-Myers Squibb Company was founded in 1887 — 97 years before Dell Technologies Inc., which was founded in 1984. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Dell Technologies Inc..
How many employees does Bristol-Myers Squibb Company have compared to Dell Technologies Inc.?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Dell Technologies Inc. employs approximately 97,000. Dell Technologies Inc. has the larger workforce at 97,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Dell Technologies Inc. headquartered?
Both Bristol-Myers Squibb Company and Dell Technologies Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Bristol-Myers Squibb Company and Dell Technologies Inc.?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Dell Technologies Inc. was founded by Michael S. Dell.
Which company has a longer operating history — Bristol-Myers Squibb Company or Dell Technologies Inc.?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Dell Technologies Inc. has been in operation for around 42 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Dell overview